Aytu BioPharma Dirección
Dirección controles de criterios 2/4
El CEO de Aytu BioPharma's es Josh Disbrow , nombrado en Apr 2015, tiene una permanencia de 9.17 años. compensación anual total es $708.00K, compuesta por 83.3% salario y 16.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.29% de las acciones de la empresa, por valor de $204.36K. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 7.9 años, respectivamente.
Información clave
Josh Disbrow
Chief Executive Officer (CEO)
US$708.0k
Compensación total
| Porcentaje del salario del CEO | 83.3% |
| Permanencia del CEO | 9.2yrs |
| Participación del CEO | 1.3% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 7.9yrs |
Actualizaciones recientes de la dirección
Recent updates
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Jun 20
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Jun 14US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Aytu BioPharma up 21% in afternoon trading
Jun 21Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now
May 15A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation
Feb 14Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts
Dec 31Aytu BioScience completes safety study in critically ill COVID-19 patients
Dec 28Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$14m |
| Dec 31 2023 | n/a | n/a | -US$18m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | US$708k | US$590k | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | n/a | n/a | -US$77m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | US$590k | US$590k | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | US$6m | US$545k | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$42m |
| Dec 31 2020 | n/a | n/a | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | US$2m | US$608k | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$25m |
| Dec 31 2019 | n/a | n/a | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$29m |
| Jun 30 2019 | US$1m | US$330k | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$12m |
| Dec 31 2018 | n/a | n/a | -US$10m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | US$606k | US$303k | -US$10m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | n/a | n/a | -US$20m |
| Sep 30 2017 | n/a | n/a | -US$21m |
| Jun 30 2017 | US$1m | US$250k | -US$23m |
Compensación vs. Mercado: La compensación total ($USD708.00K) de Josh está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD678.50K).
Compensación vs. Ingresos: La compensación de Josh ha aumentado mientras la empresa no es rentable.
CEO
Josh Disbrow (49 yo)
9.2yrs
Permanencia
US$708,000
Compensación
Mr. Joshua R. Disbrow, also known as Josh, serves as Chairman at Aytu Biopharma, Inc. He served as Chairman at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 until 2023 and...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 9.2yrs | US$708.00k | 1.29% $ 223.8k | |
| CFO, Secretary & Treasurer | 2.4yrs | US$522.84k | 0.17% $ 29.7k | |
| Chief Commercial Officer | 1.9yrs | US$540.05k | 0.41% $ 71.1k | |
| Vice President of Operations | no data | sin datos | sin datos | |
| Vice President of People & Culture | 1.4yrs | sin datos | sin datos | |
| Chief Business Officer & President of Consumer Health | 1.6yrs | US$793.41k | 0.23% $ 39.9k | |
| Senior Vice President of Research & Development | no data | sin datos | sin datos | |
| Executive VP of Finance & Business Optimization | 1.6yrs | sin datos | sin datos |
1.8yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AYTU no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 8.4yrs | US$708.00k | 1.29% $ 223.8k | |
| Independent Director | 1.9yrs | US$89.62k | 0.15% $ 26.0k | |
| Lead Independent Director | 7.9yrs | US$90.00k | 0.041% $ 7.1k | |
| Independent Director | 8.2yrs | US$70.00k | 0.17% $ 30.1k | |
| Independent Director | less than a year | US$3.31k | 0.14% $ 25.0k |
7.9yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de AYTU se considera experimentada (7.9 años de antigüedad promedio).